Adaptive Signature Design- review of the biomarker guided adaptive phase –III controlled design
نویسندگان
چکیده
منابع مشابه
Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
Biomarker-guided treatment is a rapidly developing area of medicine, where treatment choice is personalised according to one or more of an individual's biomarker measurements. A number of biomarker-guided trial designs have been proposed in the past decade, including both adaptive and non-adaptive trial designs which test the effectiveness of a biomarker-guided approach to treatment with the ai...
متن کاملThe cross-validated adaptive signature design.
PURPOSE Many anticancer therapies benefit only a subset of treated patients and may be overlooked by the traditional broad eligibility approach to design phase III clinical trials. New biotechnologies such as microarrays can be used to identify the patients that are most likely to benefit from anticancer therapies. However, due to the high-dimensional nature of the genomic data, developing a re...
متن کاملAn adaptive biomarker strategy clinical trial design
The Biomarker Strategy Design has been proposed for trials assessing the value of a biomarker in guiding treatment in oncology. In such trials, patients are randomised to a control arm, receiving the standard chemotherapy treatment, or a biomarker-directed treatment arm, when biomarker status is used to guide treatment. The randomised groups are then compared, often using a noninferiority test ...
متن کاملDesign of A Self-Tuning Adaptive Power System Stabilizer
Power system stabilizers (PSSs) must be capable of providing appropriate stabilization signals over abroad range of operating conditions and disturbances. The main idea of this paper is changing aclassic PSS (CPSS) to an adaptive PSS using genetic algorithm. This new genetic algorithm based onadaptive PSS (GAPSS) improves power system damping, considerably. The controller design issue isformula...
متن کاملAdaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients.
PURPOSE A new generation of molecularly targeted agents is entering the definitive stage of clinical evaluation. Many of these drugs benefit only a subset of treated patients and may be overlooked by the traditional, broad-eligibility approach to randomized clinical trials. Thus, there is a need for development of novel statistical methodology for rapid evaluation of these agents. EXPERIMENTA...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Contemporary Clinical Trials Communications
سال: 2019
ISSN: 2451-8654
DOI: 10.1016/j.conctc.2019.100378